ProQR Therapeutics (NASDAQ:PRQR) CEO Boer Daniel Anton De Buys 150,000 Shares

ProQR Therapeutics N.V. (NASDAQ:PRQR) CEO Boer Daniel Anton De acquired 150,000 shares of the business’s stock in a transaction that occurred on Thursday, July 9th. The stock was purchased at an average cost of $1.74 per share, with a total value of $261,000.00. Following the acquisition, the chief executive officer directly owned 300,000 shares of the company’s stock, valued at $522,000. This trade represents a 100.00% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink.

Boer Daniel Anton De also recently made the following trade(s):

• On Tuesday, July 7th, Boer Daniel Anton De bought 150,000 shares of ProQR Therapeutics stock. The stock was purchased at an average cost of $1.59 per share, for a total transaction of $238,500.00.

ProQR Therapeutics Stock Performance

Shares of NASDAQ:PRQR opened at $1.73 on Monday. The stock’s 50-day simple moving average is $1.62 and its two-hundred day simple moving average is $1.68. The stock has a market capitalization of $182.28 million, a price-to-earnings ratio of -3.46 and a beta of 0.04. ProQR Therapeutics N.V. has a 52-week low of $1.33 and a 52-week high of $3.10.

ProQR Therapeutics (NASDAQ:PRQR) last released its quarterly earnings results on Tuesday, May 12th. The biopharmaceutical company reported ($0.15) EPS for the quarter, meeting the consensus estimate of ($0.15). The firm had revenue of $2.35 million during the quarter, compared to analyst estimates of $5.19 million. ProQR Therapeutics had a negative net margin of 331.33% and a negative return on equity of 84.87%. As a group, equities analysts forecast that ProQR Therapeutics N.V. will post -0.52 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on the stock. Citigroup reiterated a “market outperform” rating on shares of ProQR Therapeutics in a research note on Wednesday, May 27th. JonesTrading decreased their target price on ProQR Therapeutics from $11.00 to $10.00 and set a “buy” rating on the stock in a report on Friday, June 26th. Wall Street Zen downgraded ProQR Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Saturday, May 16th. Chardan Capital cut their price target on ProQR Therapeutics from $4.00 to $3.00 and set a “buy” rating for the company in a report on Friday, June 26th. Finally, Weiss Ratings downgraded ProQR Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, June 23rd. Four research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, ProQR Therapeutics has an average rating of “Moderate Buy” and an average price target of $7.33.

Hedge Funds Weigh In On ProQR Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Axiom Investment Management LLC purchased a new position in ProQR Therapeutics during the first quarter valued at $53,000. Bank of America Corp DE lifted its stake in ProQR Therapeutics by 6.4% in the 1st quarter. Bank of America Corp DE now owns 185,110 shares of the biopharmaceutical company’s stock worth $300,000 after purchasing an additional 11,186 shares in the last quarter. Walleye Capital LLC boosted its holdings in shares of ProQR Therapeutics by 2.7% during the 1st quarter. Walleye Capital LLC now owns 607,529 shares of the biopharmaceutical company’s stock valued at $984,000 after purchasing an additional 15,744 shares during the last quarter. Invesco Ltd. bought a new position in shares of ProQR Therapeutics during the 4th quarter valued at about $51,000. Finally, XTX Topco Ltd grew its position in shares of ProQR Therapeutics by 1,057.4% during the fourth quarter. XTX Topco Ltd now owns 117,900 shares of the biopharmaceutical company’s stock valued at $238,000 after purchasing an additional 107,713 shares in the last quarter. Institutional investors own 32.65% of the company’s stock.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V. is a clinical-stage biotechnology company dedicated to developing RNA-based therapies for severe genetic diseases. Utilizing its proprietary Axiomer® RNA editing platform, ProQR aims to correct disease-causing mutations directly at the messenger RNA level. The company’s pipeline features several investigational candidates, including sepofarsen (formerly QR-110) for Leber congenital amaurosis type 10, QR-421a targeting Usher syndrome and certain forms of retinitis pigmentosa, and QR-313 for dystrophic epidermolysis bullosa.

Founded in 2012 and headquartered in Leiden, the Netherlands, ProQR maintains a significant presence in Cambridge, Massachusetts, to support its clinical research and regulatory initiatives.